Aligos Therapeutics reported cash of $31.1 million as of September 30, down from $77.8 million at year-end 2025. R&D decreased due to lower Phase 2 trial costs as the company initiates a Phase 1 study in China for its candidate ALG-170675.
Aligos Therapeutics reported cash of $31.1 million as of September 30, down from $77.8 million at year-end 2025. R&D decreased due to lower Phase 2 trial costs as the company initiates a Phase 1 study in China for its candidate ALG-170675.